Latest News

Keep up to date with all our latest investments, service offerings and news items.

Click here to view our latest media kit

  • November 1, 2019

    Almac Group Hosts Internationally Recognized Chemistry Forum in Belfast

  • July 8, 2019

    Arran Chemical Company forms Unique Industry – Academia Collaboration with Athlone Institute of Technology

  • February 25, 2019

    Almac Group Engages with Science Exchange to Promote US Small Molecule Analytical Services

  • January 8, 2019

    Almac Group Flows into Continuous Technology

  • January 2, 2019

    Almac Group Launches Second Line for High Throughput GMP Peptide Manufacturing

  • October 1, 2018

    Almac Group Launches Global Analytical Services Capability

  • July 27, 2018

    Almac Group Launches GMP High Throughput Peptide Manufacturing Service

  • May 1, 2018

    Almac Group Appoints David Taylor as Head of Manufacturing Operations

  • January 29, 2018

    Almac Group Appoints Dr Stefan Mix as Head of Biocatalysis

  • January 24, 2018

    Almac Group Launches Bespoke Elemental Impurities Laboratory

  • January 2, 2018

    Almac Group Launches Second Line for High Throughput GMP Peptide Manufacturing

  • December 5, 2017

    Almac Group Receives Annual Industrial Award from the Institute of Chemistry of Ireland

  • December 13, 2016

    Almac Group Appoints Professor Tom Moody as VP of Technology Development and Commercialization

  • October 14, 2016

    Almac Group Wins Prestigious Research and Development Award

  • May 23, 2016

    Almac to partner with ZYMtronix to deploy its universal enzyme immobilization platform

  • January 25, 2016

    NEW Fluorescence Lifetime Platform Unveiled at SLAS

  • November 3, 2015

    Almac Acquires Arran Chemical Company and Expands Biocatalysis Services

  • July 10, 2015

    Almac Group Appoints Dr. John Robson as VP Quality Operations

  • February 5, 2015

    Almac Group Drives Biocatalysis Leadership with a Further $7M Investment

  • December 10, 2013

    Almac wins Laboratory Team of the Year at The Irish Laboratory Awards 2013

  • November 13, 2013

    Almac’s Strengthened Facilities Accommodates Demand of Late Stage API Manufacture

  • October 22, 2013

    Novozymes Biopharma announces collaboration with Almac in Drug Manufacture, Half Life Extension and Targeting Technologies

  • October 7, 2013

    Almac Launches New [14C]-labelled ADCs Service Offering

  • May 15, 2013

    Almac secures new metagenomics and enzyme discovery program with UCL

  • February 20, 2013

    Almac Receives FDA Inspection Approval

  • January 21, 2013

    Almac Successfully Completes Knowledge Transfer Partnership with Queens University with Highest Accolade

  • January 7, 2013

    Almac and TTP Labtech form alliance in fluorescence lifetime technology

  • October 9, 2012

    Almac Concludes Commercial API Manufacturing Facility Expansion Plans

  • October 8, 2012

    Almac and DSM Sign Collaboration Agreement in Biocatalysis

  • September 17, 2012

    Almac Launches New Histone Reagents Catalog and Custom Synthesis Service

  • June 11, 2012

    Almac and VTU Technology form collaboration to provide customers with high yielding, fast-track generation of site-specific modified products

  • February 13, 2012

    selectAZyme™ grows into metabolite synthesis

  • January 23, 2012

    Almac Celebrates MHRA Audit Successes

  • January 17, 2012

    MGB Biopharma and Almac Collaborate on Contract Manufacturing Project

  • October 25, 2011

    Almac’s rapidd continuing to accelerate early stage development 2 years on

  • October 24, 2011

    Almac Invests in New Commercial API Manufacturing

  • May 4, 2011

    Almac Introduces selectAZymeTM

  • March 28, 2011

    BioFocus and Almac collaborate to offer fluorescent lifetime assays

  • November 23, 2010

    Almac discusses its investment in biocatalysis lauding cost and environmental benefits on OutsourcingPharma.com

  • October 7, 2010

    Almac continues biocatalysis business growth with a further $4m R&D investment

  • April 29, 2010

    Almac extends Site-specific PEGylation Technology to single domain antibodies

  • April 7, 2010

    New FLEXYTE® Protease Assays Enable Information-rich Output, Miniaturization and Multiplexing

  • February 26, 2010

    Almac Expands Radiolabeling Facilities to Include 14C API and IMP Supply

  • January 18, 2010

    Almac Announces that AstraZeneca is to Undertake Evaluation FLEXYTE Protein Kinase Assays

  • November 2, 2009

    Almac Launches Unique Site-specific PEGylation Technology at BIO Europe

  • October 14, 2009

    “rapidd” Accelerating Early Stage Development, Minimizing Cash Burn

  • October 13, 2009

    Almac and Edinburgh Instruments launch of FLEXYTE fluorescence lifetime assays at MipTec

  • July 21, 2009

    MHRA Grants Almac IMP License for its Radiolabeling Service

  • April 23, 2009

    Almac Launches Biocatalyst Kits

  • January 29, 2009

    Almac Promotes Biocatalysis and Radiolabeling

  • December 5, 2007

    Almac Sciences: a global supply chain approach

  • December 5, 2007

    Almac Sciences: “First in man” approach to peptides

  • March 8, 2007

    Almac Sciences Invest In Edinburgh Facility

  • February 14, 2007

    SafeBridge® Certification for Almac Sciences’ cytotoxics plant

  • February 14, 2007

    Almac Sciences and BioCatalytics Inc. to co-operate on key pharma products

  • February 14, 2007

    CPST fill-and-finish agreement for Almac Sciences’ cytotoxics

  • October 10, 2006

    Almac Sciences Scales Up for Peptides

  • February 16, 2006

    CSS Radio Goes Live; Chiral Building Blocks Range Announced

  • November 29, 2005

    CSS Focuses on Australian Market

  • November 25, 2005

    CSS Launches Global Provision of Radiolabeling Services

  • March 4, 2005

    CSS Albachem Secures a Share of £3.7 million R&D Program

  • December 21, 2004

    Chiral Consortium

  • December 7, 2004

    CSS Enters Chiral Market Through Collaborations with ChiralQuest and IEP

  • October 28, 2004

    CSS Launches Unique Consortium at CPhI

  • May 10, 2004

    CSS Acquires Controlling Interest in Peptide Company ALBACHEM

  • September 1, 2003

    Senator GEORGE MITCHELL Officially Opens New CSS Facility